Australia's Acrux rises as U.S. FDA plans to review its acne treatment gel

Acrux

13/09/2021 04:49

** Shares of Acrux Ltd  ACR.AX  rise as much as 1.9% to
A$0.13, their highest since July 28
    ** The pharma company says the U.S. FDA will review its
abbreviated new drug application for its generic version of
Dapsone gel 5%  urn:newsml:reuters.com:*:nFWN2QC0TW
    ** The Dapsone gel is used to treat acne
    ** Stock down 21.2% YTD, as of last close 
    

 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))